<p>(A) A box indicates a median and interquartile range, and error bars denote the 10th and 90th percentiles. (B) High (> 500 mIU/mL, n = 35), moderate (100–500 mIU/mL, n = 62), and low (< 100 mIU/mL, n = 46) titers. It was a significant trend that individuals with lower titers of initial anti-HBs experienced secondary vaccine response failure earlier.</p
<p>Line at GMC. A) The anti-HBs levels in the groups were not significantly different. B) The anti-H...
<p>VL, viral load; HBV, hepatitis B virus; AIDS, acquired immunodeficiency syndrome; HAART, highly a...
<p>The expected number of deaths per million primary vaccinations and revaccinations with (A) the NY...
<p>Table shows number at risk, number of subjects with undetectable HBsAb (HBsAb <10), and the perce...
Individuals with insufficient protective anti-HBs (<10 mIU/ml) classified into 3 groups (<1 mIU/ml, ...
<p>Decrease in antibody to hepatitis B surface antigen (anti-HBs) by time since vaccination, and pea...
(a). Post-vaccination HBsAb titer for patients (CKD, black symbols; n = 49) and healthy controls (HC...
<p>NOTE. CI, confidence interval; Anti-HBs, hepatitis B surface antibody; DTH, delayed-type hypersen...
<p>Percentages of responders (anti-HBs ≥ 100 mIU/ml) to hepatitis B vaccine by vaccination regimen.<...
<p>Percentages of responders (anti-HBs ≥ 10 mIU/ml) to hepatitis B vaccine by vaccination regimen.</...
(A) Individuals were grouped based on their pre-existing anti-HBs (100 mIU/ml (dark blue). (B) Geome...
Percentage of individuals with pre-existing anti-HBs 10 mIU/ml) post-booster.</p
<p>NOTE. Data are no. of participants (%) with data available, unless otherwise indicated. IQR, inte...
<p>HBV, hepatitis B virus; HAART, highly active antiretroviral therapy; OR, odds ratio; CI, confiden...
<p>Table shows number of subjects at risk, number of subjects with HBV infection, and the percent of...
<p>Line at GMC. A) The anti-HBs levels in the groups were not significantly different. B) The anti-H...
<p>VL, viral load; HBV, hepatitis B virus; AIDS, acquired immunodeficiency syndrome; HAART, highly a...
<p>The expected number of deaths per million primary vaccinations and revaccinations with (A) the NY...
<p>Table shows number at risk, number of subjects with undetectable HBsAb (HBsAb <10), and the perce...
Individuals with insufficient protective anti-HBs (<10 mIU/ml) classified into 3 groups (<1 mIU/ml, ...
<p>Decrease in antibody to hepatitis B surface antigen (anti-HBs) by time since vaccination, and pea...
(a). Post-vaccination HBsAb titer for patients (CKD, black symbols; n = 49) and healthy controls (HC...
<p>NOTE. CI, confidence interval; Anti-HBs, hepatitis B surface antibody; DTH, delayed-type hypersen...
<p>Percentages of responders (anti-HBs ≥ 100 mIU/ml) to hepatitis B vaccine by vaccination regimen.<...
<p>Percentages of responders (anti-HBs ≥ 10 mIU/ml) to hepatitis B vaccine by vaccination regimen.</...
(A) Individuals were grouped based on their pre-existing anti-HBs (100 mIU/ml (dark blue). (B) Geome...
Percentage of individuals with pre-existing anti-HBs 10 mIU/ml) post-booster.</p
<p>NOTE. Data are no. of participants (%) with data available, unless otherwise indicated. IQR, inte...
<p>HBV, hepatitis B virus; HAART, highly active antiretroviral therapy; OR, odds ratio; CI, confiden...
<p>Table shows number of subjects at risk, number of subjects with HBV infection, and the percent of...
<p>Line at GMC. A) The anti-HBs levels in the groups were not significantly different. B) The anti-H...
<p>VL, viral load; HBV, hepatitis B virus; AIDS, acquired immunodeficiency syndrome; HAART, highly a...
<p>The expected number of deaths per million primary vaccinations and revaccinations with (A) the NY...